NORMOSOL-R IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for NORMOSOL-R IN PLASTIC CONTAINER (NORMOSOL-R IN PLASTIC CONTAINER).
Normosol-R is an isotonic crystalloid solution that replaces extracellular fluid volume and electrolytes. It provides sodium, chloride, potassium, magnesium, acetate, and gluconate to maintain acid-base balance and osmotic equilibrium. Acetate and gluconate are metabolized to bicarbonate, providing an alkalinizing effect.
| Metabolism | Acetate and gluconate are metabolized primarily in the liver and tissues to bicarbonate. |
| Excretion | Renal excretion of electrolytes and water; no hepatic metabolism. >95% of administered water and electrolytes are excreted renally, with small amounts lost via feces (<2%) and insensible losses. |
| Half-life | Not applicable as a drug; the half-life of infused crystalloid components is distribution-dependent. Sodium and chloride have a terminal half-life of approximately 2-4 hours in healthy adults, reflecting renal clearance. Clinical context: Half-life prolonged in renal impairment. |
| Protein binding | Negligible (<1%) for electrolytes; not bound to plasma proteins. |
| Volume of Distribution | Sodium and chloride distribute primarily in extracellular fluid (ECF), approximately 0.2 L/kg. Clinical meaning: Expansion of ECF volume; minimal intracellular penetration. |
| Bioavailability | Intravenous: 100% (complete bioavailability). |
| Onset of Action | Intravenous: Immediate (within seconds to minutes) as plasma volume expansion and electrolyte correction begin upon infusion. |
| Duration of Action | Intravenous: 1-2 hours for volume expansion effect; electrolyte effects persist 2-6 hours depending on renal function. Clinical note: Duration is short, requiring continuous infusion for sustained effect. |
| Molecular Weight | 58.44 |
Intravenous infusion; dose determined by electrolyte and fluid requirements; typical adult dose: 250-1000 mL/hour, not to exceed 30 mL/kg/day.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in patients with severe renal impairment (GFR <30 mL/min/1.73 m²) due to risk of hyperkalemia and fluid overload. Use with caution and monitor serum potassium and fluid status in moderate impairment (GFR 30-60 mL/min/1.73 m²). No specific dose adjustment; rate and volume should be individualized. |
| Liver impairment | No specific adjustments for hepatic impairment based on Child-Pugh score; however, monitor fluid and electrolyte balance closely in patients with cirrhosis or ascites due to risk of fluid overload and electrolyte disturbances. |
| Pediatric use | Dose and rate based on body weight; typical infusion rate: 20-100 mL/kg/day, adjusted for maintenance or replacement needs; monitor serum electrolytes and fluid balance closely. |
| Geriatric use | Elderly patients may have reduced renal function; start with lower infusion rates and volumes; monitor for fluid overload and electrolyte imbalances, particularly hyperkalemia; adjust based on renal status and cardiac function. |
| 1st trimester | Normosol-R is generally considered safe during the first trimester when used as directed for fluid and electrolyte replacement. No increased risk of major birth defects has been reported, but caution is advised. |
| 2nd trimester | Safe for use during the second trimester for fluid and electrolyte management. Monitor maternal and fetal status as clinically indicated. |
| 3rd trimester | Safe for use during the third trimester, including during labor and delivery. May be used for volume expansion or resuscitation. Avoid overhydration, which may cause maternal or fetal complications. |
Clinical note
Comprehensive clinical and safety monograph for NORMOSOL-R IN PLASTIC CONTAINER (NORMOSOL-R IN PLASTIC CONTAINER).
| Placental transfer | Electrolytes and water freely cross the placenta. Transfer is rapid and complete, with equilibrium between maternal and fetal compartments. |
| Breastfeeding | Normosol-R is compatible with breastfeeding. It is unlikely to pose a risk to the nursing infant as it consists of electrolytes and water. However, maternal fluid and electrolyte status should be monitored. |
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | No teratogenic risk identified. Normosol-R (an isotonic crystalloid solution) is not associated with fetal malformations. No first-trimester concerns; second and third trimester use is safe for volume resuscitation. No fetal risk known. |
| Fetal Monitoring | Monitor maternal vital signs, fluid balance (input/output), serum electrolytes, and renal function. Fetal monitoring (heart rate, growth) if used for maternal hypotension or preeclampsia. |
| Fertility Effects | No known effect on fertility. It is a crystalloid solution with no hormonal or reproductive toxicity. |
■ FDA Black Box Warning
None
| Serious Effects |
known hypersensitivity to any componentsevere metabolic alkalosissevere hypernatremiasevere hyperchloremiasevere hyperkalemiasevere hypercalcemiasevere hyponatremia
| Precautions | Monitor serum electrolytes, fluid balance, and acid-base status, Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia, Risk of fluid overload in patients with compromised cardiovascular function, May cause metabolic alkalosis due to bicarbonate precursors |
| Food/Dietary | No direct food interactions. However, patients on potassium-restricted diets should be aware that Normosol-R contains potassium (5 mEq/L). |
| Clinical Pearls | Normosol-R is a balanced isotonic crystalloid containing electrolytes and acetate (as a bicarbonate precursor). It is preferred in metabolic acidosis due to acetate conversion to bicarbonate. Do not administer with blood products due to calcium content causing coagulation. Monitor serum potassium, especially in renal impairment. |
| Patient Advice | This solution replaces fluids and electrolytes lost during dehydration or surgery. · Tell your healthcare provider if you have kidney disease, heart failure, or are on a low-sodium diet. · Report any signs of fluid overload: shortness of breath, swelling in ankles/feet, or rapid weight gain. |
Loading safety data…